BioLife Solutions, Inc. (BLFS)
| Market Cap | 1.69B +34.3% |
| Revenue (ttm) | 106.69M +30.1% |
| Net Income | 57.98M |
| EPS | 1.16 |
| Shares Out | 48.91M |
| PE Ratio | 30.03 |
| Forward PE | 121.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,308 |
| Open | 34.62 |
| Previous Close | 34.93 |
| Day's Range | 34.38 - 34.66 |
| 52-Week Range | 17.86 - 38.10 |
| Beta | 1.92 |
| Analysts | Hold |
| Price Target | 31.29 (-9.28%) |
| Earnings Date | Aug 6, 2026 |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc... [Read more]
Financial Performance
In 2025, BioLife Solutions's revenue was $96.21 million, an increase of 28.89% compared to the previous year's $74.65 million. Losses were -$4.60 million, -77.23% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BLFS stock is "Hold." The 12-month stock price target is $31.29, which is a decrease of -9.28% from the latest price.
News
BioLife Solutions Proxy statement: Proxy filing
BioLife Solutions filed a proxy statement on September 9, 2026, providing details for shareholder voting and corporate governance matters.
BioLife Solutions Proxy statement: Proxy filing
BioLife Solutions filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
BioLife Solutions downgraded to Hold from Buy at Benchmark
Benchmark downgraded BioLife Solutions (BLFS) to Hold from Buy and removed the firm prior price target The company is set to be acquired by the end of the year, the…
BioLife Solutions reports Q2 EPS 92c vs. 32c last year
Reports Q2 revenue $28.5M, consensus $28.17M. “We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise,” said Roderick d...
BioLife Solutions Reports Second Quarter 2026 Financial Results
Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income ta...
BioLife Solutions Earnings release: Q2 2026
BioLife Solutions released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
BioLife Solutions Quarterly report: Q2 2026
BioLife Solutions has published its Q2 2026 quarterly earnings report on August 6, 2026.
BioLife Solutions downgraded to Equal Weight from Overweight at Stephens
Stephens downgraded BioLife Solutions (BLFS) to Equal Weight from Overweight with a price target of $31, down from $32, after the company entered into a definitive agreement to be acquired…
BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal
BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.
BioLife Solutions downgraded to Hold from Buy at Jefferies
Jefferies analyst Matthew Stanton downgraded BioLife Solutions (BLFS) to Hold from Buy with a price target of $31, up from $30, after Repligen (RGEN) announced a definitive agreement to acquire…
BioLife Solutions downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Yi Chen downgraded BioLife Solutions (BLFS) to Neutral from Buy with a price target of $31, down from $32, after the company entered into an agreement under…
BioLife Solutions downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded BioLife Solutions (BLFS) to Hold from Buy with a $31 price target after Repligen (RGEN) announced a definitive agreement to acquire the company for $31 per share.
BioLife Solutions downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded BioLife Solutions (BLFS) to Hold from Buy with a $31 price target after Repligen (RGEN) announced a definitive agreement to acquire the company for $31 per share. Published…
BioLife Solutions downgraded to Hold from Buy at Maxim
Maxim downgraded BioLife Solutions (BLFS) to Hold from Buy after Repligen (RGEN) announced a definitive agreement to acquire the company for $31 per share.
BioLife Solutions downgraded to Hold from Buy at Lake Street
Lake Street downgraded BioLife Solutions (BLFS) to Hold from Buy with a price target of $31, down from $33, after Repligen (RGEN) announced a definitive agreement to acquire the company…
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing ce...
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
06:01 EDT Repligen (RGEN) to acquire BioLife Solutions (BLFS) for $31 per share, or $1.5B
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B
Repligen (RGEN) and BioLife Solutions (BLFS) announced they have entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total ent...
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business
Biolife attracts takeover interest from Repligen, Bloomberg says
Biolife Solutions (BLFS) has drawn takeover interest from several parties, including Repligen (RGEN), Bloomberg’s Dinesh Nair and Michelle F. Davis report, citing people with knowledge of the matter. ...
BioLife Solutions Slides: Investor presentation
BioLife Solutions has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
BioLife Solutions reports Q1 EPS 2c, consensus 2c
Reports Q1 revenue $27.5M, consensus $25.66M. “We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million,” said CEO Roderick de…
BioLife Solutions sees 2026 revenue $112.5M-$115.0M, consensus $112.94M
16:22 EDT BioLife Solutions (BLFS) sees 2026 revenue $112.5M-$115.0M, consensus $112.94M
BioLife Solutions Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 25% year-over-year to $27.5M, led by BPM demand, with adjusted EBITDA up 15%. Guidance for 2026 revenue of $112.5–$115M and margin expansion was reaffirmed, as operational improvements and new product launches are expected to drive growth.
BioLife Solutions Earnings release: Q1 2026
BioLife Solutions released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.